Shares of DexCom (DXCM) are down $9.24, or more than 7%, to $113.68 in Monday afternoon trading after rival Abbott (ABT) announced this morning that the U.S. FDA has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring, or CGM, system sensors for integration with automated insulin delivery systems.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DXCM:
- DexCom put volume heavy and directionally bearish
- CMS earlier Basal coverage approval adds confidence for DexCom, says BofA
- DexCom CEO sells $4.23M in common stock
- Early notable gainers among liquid option names on March 2nd
- Billionaire Israel Englander Is Making Huge Bets on These 2 ‘Strong Buy’ Stocks